€
2. 70
+0.05
+1.8868%
€
- Market Cap
- P/E Ratio
- Div Yield
4,727 Volume
- Eps
€ 2.65
Previous Close Want to track ZVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ZVA closed Friday higher at €2.7, an increase of 1.8868% from Thursday's close, completing a monthly decrease of -11.6492% or -€0.36. Over the past 12 months, ZVA stock lost -35.0181%.
ZVA is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Cellectis S.A. has completed 1 stock splits, with the recent split occurring on Nov 01, 2011.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XPAR (EUR).
ZVA Chart
Cellectis S.A. (ZVA) FAQ
What is the stock price today?
The current price is €2.70.
On which exchange is it traded?
Cellectis S.A. is listed on XSTU.
What is its stock symbol?
The ticker symbol is ZVA.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Cellectis S.A. ever had a stock split?
Cellectis S.A. had 1 splits and the recent split was on Nov 01, 2011.
Cellectis S.A. Profile
| Biotechnology Industry | Healthcare Sector | Andre Choulika CEO | XSTU Exchange | FR0010425595 ISIN |
| FR Country | 216 Employees | - Last Dividend | 1 Nov 2011 Last Split | - IPO Date |
Overview
Cellectis S.A. is a pioneering clinical-stage biotechnology company focused on the development of innovative gene-editing therapies. Founded in 1999 and headquartered in Paris, France, Cellectis leverages its expertise in gene editing to create a portfolio of allogeneic chimeric antigen receptor (CAR) T-cell product candidates aimed at treating a wide range of cancers. The company has distinguished itself in the biotech industry through strategic alliances with notable biopharmaceutical companies such as Allogene Therapeutics, Inc., Les Laboratoires Servier, Iovance Biotherapeutics, Inc., and AstraZeneca, showcasing its commitment to advancing the field of gene-edited immunotherapy.
Products and Services
- ALLO-715 and ALLO-605 - These are allogeneic CAR T-cell therapies in development for the treatment of multiple myeloma, a type of cancer that affects plasma cells.
- ALLO-501 - A therapy aimed at treating large B-cell lymphoma, a common form of non-Hodgkin lymphoma, through the use of allogeneic CAR T cells.
- ALLO-316 - This product candidate targets CD70 through the utilization of allogeneic engineered CAR T cells to potentially treat various cancers.
- ALLO-819 - A development aimed at addressing acute myeloid leukemia (AML) using allogeneic CAR T-cell therapy.
- ALLO-213 - This therapy is in the pipeline for the treatment of small cell lung cancer, showcasing Cellectis' expansion into solid tumor indications.
- ALLO-182 - A CAR T-cell therapy designed for the treatment of gastric and pancreatic cancer, highlighting the versatility of Cellectis' platform.
- UCART22 - Focused on relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), this product utilizes UCART technology for targeting cancer cells.
- UCART123 - This candidate is designed for the treatment of acute myeloid leukemia (AML) and showcases the potential of Cellectis' UCART platform.
- UCART 20x22 - Aimed at relapsed or refractory B-Cell non-Hodgkin’s lymphoma, demonstrating the applicability of the UCART platform across varied lymphomas.
- cema-cel - Developed for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, highlighting innovative approaches to leukemia therapy.
Contact Information
Address: 8, rue de la Croix Jarry
Phone: 33 1 81 69 16 00
Website: https://www.cellectis.com
